CIK 0000882095
- Large accelerated filer
GILEAD SCIENCES, INC.
Sign in to watch- Ticker
- GILD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943047598
- Phone
- +1 650-574-3000
- Business address
- 333 LAKESIDE DR, FOSTER CITY, CA, 94404
- Former names
- GILEAD SCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $36,996,096
- in 12 filings, $37.0M under 10b5-1 plans
Net −$36,996,096. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-29 | Dickinson Andrew D Chief Financial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −26,170 | 130,860 | ||
| 2024-11-29 | Dickinson Andrew D Chief Financial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −18,630 | 0 | ||
| 2024-11-29 | Dickinson Andrew D Chief Financial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −33,660 | 0 | ||
| 2024-11-29 | Dickinson Andrew D Chief Financial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −60,885 | 0 | ||
| 2024-11-29 | Dickinson Andrew D Chief Financial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −43,340 | 0 | ||
| 2024-11-29 | Dickinson Andrew D Chief Financial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −65,960 | 0 | ||
| 2024-11-27 | Parsey Merdad Chief Medical Officer | Option exercise 10b5-1 | +57,294 | $57.92 | $3.3M | 156,893 |
| 2024-11-27 | Parsey Merdad Chief Medical Officer | Option exercise 10b5-1 | +88,119 | $65.38 | $5.8M | 245,012 |
| 2024-11-27 | Parsey Merdad Chief Medical Officer | Sale 10b5-1 | −57,294 | $91.79 | $5.3M | 187,718 |
| 2024-11-27 | Parsey Merdad Chief Medical Officer | Sale 10b5-1 | −88,119 | $92.00 | $8.1M | 99,599 |
| 2024-11-27 | Parsey Merdad Chief Medical Officer | Sale 10b5-1 | −5,200 | $91.80 | $477K | 94,399 |
| 2024-11-27 | Parsey Merdad Chief Medical Officer | Sale 10b5-1 | −3,199 | $91.80 | $294K | 91,200 |
| 2024-11-27 | Parsey Merdad Chief Medical Officer | Sale 10b5-1 | −10,399 | $92.00 | $957K | 80,801 |
| 2024-11-27 | Parsey Merdad Chief Medical Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −57,294 | 64,376 | ||
| 2024-11-27 | Parsey Merdad Chief Medical Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −88,119 | 196 | ||
| 2024-11-26 | Bluestone Jeffrey Director | Option exercise | +5,879 | $61.17 | $360K | 11,587 |
| 2024-11-26 | Bluestone Jeffrey Director | Option exercise | +4,121 | $61.35 | $253K | 15,708 |
| 2024-11-26 | Bluestone Jeffrey Director | Sale | −6,788 | $91.39 | $620K | 8,920 |
| 2024-11-26 | Bluestone Jeffrey Director | Option exercise · Non-qualified Stock Option (Right to Buy) | −5,879 | 0 | ||
| 2024-11-26 | Bluestone Jeffrey Director | Option exercise · Non-qualified Stock Option (Right to Buy) | −4,121 | 11,730 |
Page 23 of 30 · 599 trades